What is the Regeneron Pharmaceuticals Inc (REGN) price today?

The price of Regeneron Pharmaceuticals Inc (REGN) today is $746.5. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/REGN

Buy & Sell Regeneron Pharmaceuticals Inc (REGN) – Regeneron Pharmaceuticals Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

Regeneron Pharmaceuticals (REGN) trades at $746.00, down 1.26% on the day, with technical indicators showing a bearish bias amid neutral oscillators. The company maintains strong profitability with a net income margin of 31.41% and has consistently beaten earnings estimates in recent quarters. Recent developments include a strategic radiopharmaceutical collaboration with Telix and EU approval for expanded pediatric use of Dupixent, signaling pipeline growth.

Outlook remains positive driven by robust fundamentals and analyst consensus, though near-term technical weakness and competitive pressures pose risks. The stock offers potential upside to the consensus price target of $862.17, supported by earnings momentum and strategic expansions in oncology and immunology.

Read full analysis

Key Stats

Market Cap
$79.71B
Sector
Health
3M Drawdown
-8.73%
Enterprise Value
$73.81B
Dividend Yield
0.5%
Typical Hold Time
94 days

$746.5

52W Low: $483.07

05 Jun 2025

52W High: $812.27

07 Jan 2026

Regeneron Pharmaceuticals Inc (REGN) is currently valued at a market capitalization of $79.71B, with an enterprise value of $73.81B. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $483.07 and a high of $812.27, highlighting its annual price range. Over the past three months, Regeneron Pharmaceuticals Inc has recorded a drawdown of -8.73%, reflecting recent price volatility. Regeneron Pharmaceuticals Inc offers a dividend yield of 0.5%, with the most recent dividend of $0.94 paid on 20 Feb 26. On average, investors hold Regeneron Pharmaceuticals Inc for approximately 94 days, indicating typical investor behavior on the platform.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Technical Indicators

Overall Summary

Bearish (10)Neutral (7)Bullish (10)

News

Globe Newswire4 day ago

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

Globe Newswire4 day ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Globe Newswire7 day ago

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

Globe Newswire7 day ago

Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033

Benzinga9 day ago

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$79.71B
Sector
Health
3M Drawdown
-8.73%
Enterprise Value
$73.81B
Dividend Yield
0.5%
Typical Hold Time
94 days

$746.5

52W Low: $483.07

05 Jun 2025

52W High: $812.27

07 Jan 2026

Let’s invest in this asset by signing up or download!

Buy & Sell Regeneron Pharmaceuticals Inc (REGN) – Regeneron Pharmaceuticals Inc Price Today

Aura AI Summary

Key Stats

About Regeneron Pharmaceuticals Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store